Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (GIST)
Conditions
Interventions
Olaratumab
Locations
13
United States
ImClone Investigational Site
Chicago, Illinois, United States
ImClone Investigational Site
Boston, Massachusetts, United States
ImClone Investigational Site
Edegem, Belgium
ImClone Investigational Site
Leuven, Belgium
ImClone Investigational Site
Bad Saarow, Germany
ImClone Investigational Site
Berlin, Germany
Start Date
August 1, 2011
Primary Completion Date
May 1, 2012
Completion Date
November 1, 2012
Last Updated
March 9, 2017
NCT03594422
NCT06655246
NCT07072143
NCT05009927
NCT00780494
NCT02574663
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions